---
layout: default
title: Estradiol Valerate
parent: 僅模型預測 (L5)
nav_order: 324
evidence_level: L5
indication_count: 10
---

# Estradiol Valerate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Estradiol Valerate: From Estrogen Deficiency Therapy to Symptomatic Form of Fragile X Syndrome in Female Carrier

## One-Sentence Summary

Estradiol valerate is a synthetic estrogen generically used for hormone replacement and estrogen-deficiency conditions; specific NPRA-approved indication text was not captured in this data pull.
The TxGNN model predicts a possible association with **Symptomatic Form of Fragile X Syndrome in Female Carrier**,
but this is currently supported by **0 clinical trials** and **0 publications** — a pure computational signal with no direct clinical evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in NPRA license data (Estradiol valerate is generically classified as an estrogen used in hormone replacement therapy) |
| Predicted New Indication | Symptomatic form of fragile X syndrome in female carrier |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DG002, DrugBank query pending). Based on known information, estradiol valerate is a synthetic ester of 17β-estradiol that acts as an estrogen receptor agonist, and is generically used across estrogen-deficiency conditions (e.g., menopausal hormone therapy, hypoestrogenism).

The proposed link to fragile X syndrome rests on an indirect biological chain: female carriers of the FMR1 premutation can develop FXPOI (fragile X-associated primary ovarian insufficiency), a condition that — like primary ovarian failure — is treated with estrogen replacement. This gives the prediction a theoretically plausible pathway.

However, this mechanistic link is inferential only. There is no clinical trial or literature evidence in this evidence pack connecting estradiol valerate directly to fragile X syndrome (symptomatic carrier form) — the prediction is driven purely by the TxGNN model's score (rank 1341 in its internal ranking) rather than by observed drug-disease association in trials or publications. It should be treated as a hypothesis-generating signal, not a validated repurposing candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Malaysia Market Information

NPRA records confirm **3 active registrations** for Estradiol valerate, with overall market status **Marketed**. License-level details (license number, product name, dosage form, and approved indication text) were not captured in this data pull — see Data Gap DG001 (Blocking) below.

---

## Safety Considerations

Please refer to the package insert for safety information. Note that TFDA/NPRA package insert warnings and contraindications are currently a **Blocking** data gap (DG001) — this must be resolved before any formal safety (S1) evaluation can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked TxGNN prediction (fragile X syndrome, symptomatic female carrier form) has zero supporting clinical trials or literature (Evidence Level L5, Decision Stage S0), and the drug's core safety data (warnings, contraindications) is blocked pending TFDA label retrieval (DG001), which prevents any safety-stage review.

**To proceed, the following is needed:**
- TFDA/NPRA package insert — warnings and contraindications (resolves DG001, currently Blocking)
- Mechanism of action data from DrugBank (resolves DG002)
- Malaysia license-level product details (license numbers, product names, dosage forms, approved indication text)
- If pursuing a repurposing signal for this drug, consider evaluating **primary ovarian failure** (rank 2 in the prediction list) instead — it has substantially stronger supporting evidence (50 clinical trials, 20 publications identified) than the top-ranked but evidence-free candidate reported here
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

